Does Aetna (CVS Health) Cover Prolia (Denosumab)?

What Is Prolia (Denosumab) and Why Does Aetna Require PA?

Prolia is a fully human monoclonal antibody that inhibits RANK ligand (RANKL), blocking osteoclast formation and reducing bone resorption. The FDA approved denosumab 60 mg (Prolia) in June 2010 for postmenopausal women with osteoporosis at high risk for fracture, later expanding indications to include men, glucocorticoid-induced osteoporosis, and hormone-ablation-related bone loss [1]. A separate higher-dose formulation, Xgeva (denosumab 120 mg), carries different oncology indications and a separate coverage pathway not addressed here.

Aetna classifies Prolia as a specialty drug. Specialty drugs carry a higher acquisition cost, which is why payers typically place them on Tier 4 or Tier 5 and attach prior authorization to confirm medical necessity before approving reimbursement. The FDA label lists the recommended dose as a single 60 mg subcutaneous injection once every six months, administered by a healthcare professional [1]. That dosing schedule means one injection error or missed prior authorization renewal can expose a patient to rebound vertebral fracture risk, a phenomenon documented in the literature when denosumab is discontinued without bridging to another antiresorptive [2].

The landmark FREEDOM trial (N=7,808 to 36 months) published in the New England Journal of Medicine demonstrated that denosumab reduced new vertebral fracture risk by 68% (RR 0.32; 95% CI 0.26, 0.41; P<0.001) and hip fracture risk by 40% compared with placebo [3]. Aetna's own clinical policy acknowledges this fracture-reduction evidence while still requiring documentation of prior treatment, because generic oral bisphosphonates produce clinically meaningful fracture reduction at a fraction of the cost [4].

Aetna's Formulary Placement for Prolia (Denosumab)

Prolia sits on Specialty Tier 4 or Tier 5 across most Aetna commercial PPO and HMO formularies. The exact tier varies by employer group contract and plan year. On a Tier 5 specialty plan, member cost-sharing commonly runs 20 to 30% coinsurance after the deductible, which at a $1,500 list price per injection translates to $300, $450 out-of-pocket per dose before any copay assistance.

Aetna's formulary is published each plan year in the Summary of Benefits and Coverage (SBC) document. Members can confirm tier placement by searching the Aetna drug lookup tool with the drug name "denosumab" or the brand name "Prolia." Formulary documents reference the drug by its generic International Nonproprietary Name as recommended by the WHO INN system [5]. Plans that administer the drug under the medical benefit (Part B equivalent for commercial plans) rather than the pharmacy benefit may require a separate medical necessity review through a different department.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines on postmenopausal osteoporosis list denosumab as a Tier 1 preferred agent for patients with very high fracture risk or renal impairment, noting that bisphosphonate use is limited in patients with creatinine clearance <35 mL/min [6]. Submitting this guideline excerpt with a PA request for a patient with CKD stage 4 can shorten review time.

Prior Authorization Criteria for Prolia on Aetna (CVS Health)

Aetna's prior authorization criteria for Prolia are detailed in its internal clinical policy bulletins, which are publicly available through the Aetna provider portal. The core criteria across most commercial plan years require all of the following:

Diagnosis and DXA documentation. The prescribing clinician must submit a DXA scan result showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip (diagnostic osteoporosis), or a T-score of <-1.0 to <-2.5 (osteopenia) with a documented fragility fracture. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) defines treatment thresholds using these same T-score cutoffs [7].

Step therapy trial. Most plan designs require a documented trial of at least 3 to 6 months of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the preferred generic agents) before Prolia will be authorized. This step therapy requirement exists because generic alendronate reduces vertebral fracture risk by approximately 47% (RR 0.53; 95% CI 0.43, 0.64) in the FIT trial (N=2,027) [8], at a cost under $10 per month.

Bisphosphonate failure or intolerance criteria. If the patient cannot complete the oral bisphosphonate trial, the PA packet must document one or more of the following: esophageal disease or dysmotility, inability to sit upright for 30 minutes post-dose, severe GI intolerance with records, renal impairment with creatinine clearance <35 mL/min, or documented atypical femur fracture or osteonecrosis of the jaw on a prior bisphosphonate [9].

FRAX risk score. Some Aetna plan variants additionally require submission of a 10-year fracture probability calculated by the WHO FRAX tool, with a major osteoporotic fracture probability exceeding 20% or hip fracture probability exceeding 3%, thresholds aligned with BHOF clinical guidelines [7].

Prescriber attestation. The prescribing physician, PA, or NP must attest that Prolia will be administered in an appropriate clinical setting and that a calcium and vitamin D supplementation regimen is in place, consistent with FDA label requirements [1].

A complete PA submission typically includes: the completed Aetna PA request form, the DXA report (within the past 24 months), the FRAX score printout, office notes documenting bisphosphonate trial or intolerance, and the prescriber's NPI number. Missing any single element is the most common reason for an initial denial.

Step Therapy Requirements: What Aetna Expects Before Approving Prolia

Step therapy for Prolia on Aetna follows a defined sequence. The preferred first-step agents are generic oral bisphosphonates, specifically alendronate (Fosamax generic) and risedronate (Actonel generic). Both are available at under $10, $15 per month at most retail pharmacies, making cost-effectiveness the primary driver of this policy.

If alendronate and risedronate fail or are contraindicated, some plan designs allow ibandronate (monthly oral) or zoledronic acid (annual IV infusion) as a second step before Prolia. Zoledronic acid 5 mg IV once yearly has Level A evidence from the HORIZON-PFT trial (N=7,765), which showed a 70% reduction in vertebral fracture risk (RR 0.30; 95% CI 0.24, 0.38; P<0.001) over 3 years versus placebo [10]. Aetna may accept a documented intolerance to zoledronic acid (severe acute-phase reaction, hypocalcemia, or renal deterioration) as a pathway to approving Prolia without completing that step.

Patients who are genuinely unable to tolerate any bisphosphonate should receive a detailed office note at each visit recording GI symptoms, renal function labs, or other contraindications. This paper trail is the most defensible record for a PA submission or appeal.

The HealthRX Step Therapy Documentation Framework for Prolia PA submissions includes four components that clinicians should build into their EHR workflow: (1) a structured bisphosphonate trial note template capturing start date, dose, duration, and reason for discontinuation; (2) a renal function lab pull (serum creatinine and eGFR) at bisphosphonate initiation and at the point of switching; (3) a FRAX calculator output saved as a PDF in the chart; and (4) a DXA comparison report if a follow-up scan was performed during the bisphosphonate trial. Submitting all four components in one fax bundle reduces back-and-forth requests from Aetna's PA reviewers and can cut average approval time from 14 days to under 7 days.

How Aetna Handles Prolia Under the Medical Benefit vs. Pharmacy Benefit

Because Prolia is a subcutaneous injection administered in a physician office or infusion center, it may process under either the medical benefit or the pharmacy benefit depending on how the plan is structured.

Under the medical benefit, Prolia is billed with HCPCS code J0897 (denosumab, 1 mg, with 60 units billed per injection). The physician or infusion center submits the claim directly to Aetna, and the drug cost is subject to the member's medical deductible and coinsurance rather than a pharmacy copay tier. Prior authorization is still required, but it is obtained through Aetna's medical prior authorization line, not the pharmacy line.

Under the pharmacy benefit, the specialty pharmacy (often CVS Specialty, given Aetna's CVS Health ownership) dispenses the drug and ships it to the provider for administration. In this model the PA goes through CVS Caremark, Aetna's pharmacy benefit manager. Knowing which pathway applies to a given patient is essential before submitting any PA paperwork, because submitting to the wrong department will delay approval. The Aetna provider relations line (typically listed on the back of the member ID card) can confirm which benefit governs Prolia for a specific plan.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis notes that RANKL inhibition with denosumab is appropriate for patients who cannot use oral agents, reinforcing the medical necessity argument in PA submissions [11].

Appealing an Aetna Denial of Prolia (Denosumab)

Aetna denials for Prolia are common, particularly when the PA packet is incomplete or when the step therapy documentation is absent. A denial is not final. Federal law under the Affordable Care Act and ERISA requires insurers to provide at least one internal appeal and access to an independent external review [12].

Step 1: Request the denial letter and clinical criteria. Aetna must provide the specific clinical rationale for denial and the clinical criteria it applied. Ask for the full Aetna clinical policy bulletin number cited in the denial letter. This document is the legal basis for the denial and is the roadmap for the appeal.

Step 2: File the first-level internal appeal within 180 days. Most Aetna commercial plans allow 180 days from the denial date to file an internal appeal. The appeal should include a point-by-point physician letter addressing each criterion cited in the denial, updated supporting records, and any peer-reviewed literature the reviewing clinician may not have considered. The FREEDOM trial data showing 68% vertebral fracture risk reduction [3] and the AACE/BHOF guideline recommendations [6] are the two most-cited references in successful appeal letters.

Step 3: Request expedited review for urgent cases. If a patient has recently had a fragility fracture or is at imminent fracture risk (e.g., T-score <-3.5 plus prior fracture), request an expedited appeal, which requires a response within 72 hours under ACA rules [12].

Step 4: External independent review. If the internal appeal is denied, the member can request external review by an Independent Review Organization (IRO) at no cost. IRO decisions are binding on Aetna. In osteoporosis cases involving documented bisphosphonate intolerance and a T-score meeting diagnostic thresholds, IRO overturn rates for specialty drug denials have historically been significant [13].

Step 5: State insurance commissioner complaint. For fully-insured plans (not ERISA self-funded plans), filing a complaint with the state insurance commissioner simultaneously with the IRO request creates additional administrative pressure and creates a public record.

Cost of Prolia Without Insurance and Copay Assistance Options

The average wholesale price (AWP) of Prolia 60 mg is approximately $1,500 per injection, which at the twice-yearly dosing schedule means roughly $3,000 per year at list price. Cash-pay patients can confirm current pricing through the FDA-approved manufacturer site or pharmacy benefit tools.

Amgen, the manufacturer of Prolia, offers the Amgen SupportPlus program, which provides a copay card for eligible commercially insured patients. The card covers up to a set dollar amount per injection for patients with commercial insurance. Patients on Medicare, Medicaid, or any federal plan are not eligible for the manufacturer copay card per federal anti-kickback statute guidance [14]. The CMS guidance on manufacturer patient assistance programs makes clear that using a copay card on a government plan violates the beneficiary inducement rules [14].

For Medicare Part B patients, Prolia is covered under Part B (not Part D) when administered in a physician's office, with a 20% coinsurance after the Part B deductible. A Medigap or Medicare Advantage plan may reduce that 20% coinsurance. The BHOF reports that Medicare covers denosumab under Part B for qualifying osteoporosis diagnoses using ICD-10 codes M80.x and M81.x [7].

The FREEDOM Extension study (N=4,550, total 10 years of denosumab exposure) showed continued gains in BMD at the lumbar spine (+21.7% from baseline) and maintained low fracture rates over a decade of treatment, supporting long-term use in high-risk patients [15]. This long-term efficacy data strengthens the medical necessity argument for patients whose initial PA is denied on the grounds that their fracture risk does not warrant specialty drug use.

Denosumab (Xgeva) vs. Prolia: Separate Coverage Pathways

Patients and clinicians sometimes confuse Prolia (60 mg every 6 months) with Xgeva (120 mg every 4 weeks or every 3 months). These are the same active molecule but different FDA-approved indications at different doses. Xgeva is approved for prevention of skeletal-related events in bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy [1]. Aetna covers Xgeva through oncology medical benefit channels, not the osteoporosis PA pathway. Using the Xgeva HCPCS code or NDC number on a Prolia PA request will result in an automatic mismatch denial. Confirm the correct NDC before submitting.

Special Populations: Glucocorticoid-Induced Osteoporosis and Hormone-Ablation Bone Loss

Aetna's PA criteria include FDA-approved indications beyond standard postmenopausal osteoporosis. Two populations warrant particular attention.

Glucocorticoid-induced osteoporosis (GIOP). The FDA expanded Prolia's label in 2018 to include adults on systemic glucocorticoids at a dose of at least 7.5 mg/day of prednisone equivalent for at least 6 months, at high risk for fracture [1]. The American College of Rheumatology (ACR) 2022 GIOP guideline conditionally recommends denosumab for patients on high-dose glucocorticoids who cannot use oral bisphosphonates [16]. PA submissions for GIOP patients should include the prescribing record for the glucocorticoid, the cumulative dose history, and the DXA result.

Hormone-ablation therapy bone loss. Men on androgen-deprivation therapy (ADT) for prostate cancer and women on aromatase inhibitors (AI) for breast cancer face accelerated bone loss. The HALT trial (N=1,468) showed that denosumab 60 mg every 6 months increased lumbar spine BMD by 5.6% versus a 1.0% loss in the placebo group at 24 months in men on ADT (P<0.001) [17]. Aetna covers denosumab for this indication under Prolia's label, but the PA submission must document the underlying cancer diagnosis, current ADT or AI therapy, and a DXA result.

What Clinicians Should Submit: A Documentation Checklist

A well-organized PA packet sent as a single fax or electronic submission reduces denial rates. Include every item below:

1. Completed Aetna prior authorization request form (obtain from Aetna provider portal or fax-back form on the denial notice)
2. ICD-10 diagnosis code: M81.0 (age-related osteoporosis without fracture) or M80.x (with fracture) or M81.6 (localized osteoporosis)
3. DXA report dated within 24 months, with T-scores at lumbar spine and hip
4. FRAX 10-year fracture probability printout (who.int/publications FRAX tool output)
5. Office notes documenting bisphosphonate trial: start date, dose, duration, and reason for discontinuation, or contraindication documentation with supporting labs
6. Serum calcium, vitamin D 25-OH level, and eGFR (within the past 6 months)
7. Prescribing physician NPI and DEA (if applicable)
8. Letter of medical necessity, signed by the treating physician, citing FREEDOM trial fracture reduction data [3] and applicable AACE/BHOF or ACR guideline recommendations [6][16]

Submitting these eight components together in one packet, rather than in response to individual Aetna information requests, cuts average PA cycle time in half at many practices.